Vaxcyte stock rises 6.82 percent to EUR 58.75 after-hours

Published on 10/15/2026 at 21:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaxcyte stock costs EUR 58.75 on October 15, 2026, up 6.82 percent versus Frankfurt close. Cantor set a USD 120.00 target on October 12, 2026.

Price movement and valuation

Vaxcyte stock stood 6.82 percent above the Frankfurt close on October 15, 2026.
Cantor Fitzgerald set a USD 120.00 price target on October 12, 2026.
Vaxcyte stock costs EUR 58.75 at Lang & Schwarz on October 15, 2026 at 9:48 p.m. CEST, 6.82 percent above the Frankfurt close of October 9, 2026.
Vaxcyte had a USD 10.0 billion market capitalization on October 15, 2026.

PCVX, US92243G1085, Illustration mit AI erstellt.

Vaxcyte stock was trading 6.82 percent above the Frankfurt close on October 15, 2026, as the euro quote moved to EUR 58.75 after hours. The latest analyst marker is Cantor Fitzgerald's USD 120.00 target, set on October 12, 2026. At Lang & Schwarz, the stock stood at EUR 58.75 on October 15, 2026 at 9:48 p.m. CEST, versus the Frankfurt close of October 9, 2026 at EUR 55.00.

Analyst target reaches USD 120.00

According to Investing.com on October 12, 2026, Cantor Fitzgerald initiated a USD 120.00 target and maintained an Overweight rating. Against the USD 65.36 primary-market price at the latest October 15, 2026 quote, that target is 83.56 percent higher. The same report cited financing pressure and a near-term catalyst path as factors weighing on the shares.

52-week range sets the frame

Vaxcyte's primary-market quote was USD 65.36 at 3:56 p.m. ET on October 15, 2026. Its 52-week range was USD 39.87 to USD 90.75, placing the price 27.98 percent below the high and 63.96 percent above the low. Trading volume reached 1,806,515 shares against an average of 1,821,959 shares in the same market snapshot.

On October 5, 2026, Vaxcyte had reported OPUS-1 Phase 3 results for VAX-31 in a release carried by Vaxcyte. The company said further adult trial results are expected in the first half of 2027.

Valuation and upcoming milestones

Vaxcyte's market capitalization was USD 10.0 billion on October 15, 2026, while its price-to-earnings ratio was negative 8.57 and its dividend yield was 0.00 percent. The company is developing VAX-31 as a 31-valent pneumococcal conjugate vaccine and is also evaluating the candidate in an infant program. The investor-relations calendar lists the company's fourth-quarter and full-year 2025 financial results event, but no future reporting date is stated there.

Comparison with peers

Vaxcyte: plus 6.82 percent, P/E negative 8.57, market capitalization USD 10.0 billion
Moderna (Nasdaq, USD): plus 4.10 percent, P/E negative 29.74, market capitalization USD 94.1 billion
Pfizer (NYSE, USD): plus 0.86 percent, P/E 38.98, market capitalization USD 167.9 billion

Euro quote after the Xetra close

The after-hours euro quote was EUR 58.75 at Lang & Schwarz on October 15, 2026 at 9:48 p.m. CEST, 6.82 percent above the Frankfurt close of October 9, 2026 at EUR 55.00. The comparison places the German-market indication above its last dated Frankfurt close while the primary Nasdaq quote remained at USD 65.36 earlier in the U.S. session. The further course of trading is shown by the continuously updated real-time quote of Vaxcyte stock.